These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1361349)

  • 1. Immunotherapy of HIV-seropositive patients: preliminary report on a dose-ranging study.
    Slade H; Turner J; Abrams C; Carlo D; Salk J
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1329-31. PubMed ID: 1361349
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial.
    Trauger RJ; Daigle AE; Giermakowska W; Moss RB; Jensen F; Carlo DJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S74-82. PubMed ID: 7552517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 immunogen induction of HIV-1-specific delayed-type hypersensitivity: results of a double-blind, adjuvant-controlled, dose-ranging trial.
    Turner JL; Trauger RJ; Daigle AE; Carlo DJ
    AIDS; 1994 Oct; 8(10):1429-35. PubMed ID: 7818813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells.
    Trauger RJ; Ferre F; Daigle AE; Jensen FC; Moss RB; Mueller SH; Richieri SP; Slade HB; Carlo DJ
    J Infect Dis; 1994 Jun; 169(6):1256-64. PubMed ID: 7910836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization.
    Gringeri A; Santagostino E; Mannucci PM; Tradati F; Cultraro D; Buzzi A; Criscuolo M; David A; Guillemot L; Barré-Sinoussi F
    J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):978-88. PubMed ID: 7914235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up.
    Levine AM; Groshen S; Allen J; Munson KM; Carlo DJ; Daigle AE; Ferre F; Jensen FC; Richieri SP; Trauger RJ; Parker JW; Salk PL; Salk J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):351-64. PubMed ID: 8601221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.
    Peters BS; Cheingsong-Popov R; Callow D; Foxall R; Patou G; Hodgkin K; Weber JN
    J Infect; 1997 Nov; 35(3):231-5. PubMed ID: 9459393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects.
    Moss RB; Giermakowska W; Lanza P; Turner JL; Wallace MR; Jensen FC; Theofan G; Richieri SP; Carlo DJ
    Viral Immunol; 1997; 10(4):221-8. PubMed ID: 9473153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salk's HIV immunogen: an immune-based therapy in human trials since 1988.
    Crit Path AIDS Proj; 1994-1995 Winter; (No 30):1, 20-3. PubMed ID: 11362152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivated HIV-1 Immunogen: impact on markers of disease progression.
    Moss RB; Ferré F; Trauger R; Jensen F; Daigle A; Richieri SP; Carlo DJ
    J Acquir Immune Defic Syndr (1988); 1994; 7 Suppl 1():S21-7. PubMed ID: 7910207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen.
    Moss RB; Wallace MR; Giermakowska WK; Webb E; Savary J; Chamberlin-Brandt C; Theofan G; Musil R; Richieri SP; Jensen FC; Carlo DJ
    J Infect Dis; 1999 Sep; 180(3):641-8. PubMed ID: 10438350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early clinical markers and CD4 percentage in subjects with human immunodeficiency virus infection.
    Wallace MR; Moss RB; Beecham HJ; Grace CJ; Hersh EM; Peterson E; Murphy R; Shepp DH; Siegal FP; Turner JL; Safrin S; Carlo DJ; Levine AM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(4):358-62. PubMed ID: 8673544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine-induced HIV seropositivity: a problem on the rise.
    Van Braeckel E; Koutsoukos M; Bourguignon P; Clement F; McNally L; Leroux-Roels G
    J Clin Virol; 2011 Apr; 50(4):334-7. PubMed ID: 21300566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant.
    Moss RB; Webb E; Giermakowska WK; Jensen FC; Savary JR; Wallace MR; Carlo DJ
    J Acquir Immune Defic Syndr; 2000 Jul; 24(3):264-9. PubMed ID: 10969351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed-type hypersensitivity responses to HIV Gag p24 relate to clinical outcome after peptide-based therapeutic immunization for chronic HIV infection.
    Kran AM; Sommerfelt MA; Baksaas I; Sørensen B; Kvale D
    APMIS; 2012 Mar; 120(3):204-9. PubMed ID: 22339677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals.
    Zunich KM; Lane HC; Davey RT; Falloon J; Polis M; Kovacs JA; Masur H
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1335. PubMed ID: 1466952
    [No Abstract]   [Full Text] [Related]  

  • 17. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques.
    Silvera P; Savary JR; Livingston V; White J; Manson KH; Wyand MH; Salk PL; Moss RB; Lewis MG
    Vaccine; 2004 Dec; 23(6):827-39. PubMed ID: 15542208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300.
    Churdboonchart V; Sakondhavat C; Kulpradist S; Na Ayudthya BI; Chandeying V; Rugpao S; Boonshuyar C; Sukeepaisarncharoen W; Sirawaraporn W; Carlo DJ; Moss R
    Clin Diagn Lab Immunol; 2000 Sep; 7(5):728-33. PubMed ID: 10973445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development.
    Franco D; Li W; Qing F; Stoyanov CT; Moran T; Rice CM; Ho DD
    Vaccine; 2010 Aug; 28(35):5676-85. PubMed ID: 20600494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy.
    Asjö B; Stavang H; Sørensen B; Baksaas I; Nyhus J; Langeland N
    AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1357-65. PubMed ID: 12487807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.